Details

Autor(en) / Beteiligte

• Deng, Rong
• Gibiansky, Leonid
• Lu, Tong
• Flowers, Christopher R.
• Sehn, Laurie H.
• Liu, Qi
• Agarwal, Priya
• Liao, Michael Z.
• Dere, Randall
• Lee, Calvin
• Man, Gabriel
• Hirata, Jamie
• Li, Chunze
• Miles, Dale

Titel

Population pharmacokinetics and exposure–response analyses of polatuzumab vedotin in patients with previously untreated DLBCL from the POLARIX study

Ist Teil von

• CPT: pharmacometrics and systems pharmacology, 2024-06, Vol.13 (6), p.1055-1066

Ort / Verlag

United States: John Wiley & Sons, Inc

Erscheinungsjahr

2024

Quelle

MEDLINE

Beschreibungen/Notizen

• Polatuzumab vedotin is a CD79b‐directed antibody–drug conjugate that targets B cells and delivers the cytotoxic payload monomethyl auristatin E (MMAE). The phase III POLARIX study (NCT03274492) evaluated polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone (R‐CHP) as first‐line treatment of diffuse large B‐cell lymphoma (DLBCL). To examine dosing decisions for this regimen, population pharmacokinetic (popPK) analysis, using a previously developed popPK model, and exposure–response (ER) analysis, were performed. The popPK analysis showed no clinically meaningful relationship between cycle 6 (C6) antibody‐conjugated (acMMAE)/unconjugated MMAE area under the concentration–time curve (AUC) or maximum concentration, and weight, sex, ethnicity, region, mild or moderate renal impairment, mild hepatic impairment, or other patient and disease characteristics. In the ER analysis, C6 acMMAE AUC was significantly associated with longer progression‐free and event‐free survival (both p = 0.01). An increase of <50% in acMMAE/unconjugated MMAE exposure did not lead to a clinically meaningful increase in adverse events of special interest. ER data and the benefit–risk profile support the use of polatuzumab vedotin 1.8 mg/kg once every 3 weeks with R‐CHP for six cycles in patients with previously untreated DLBCL.